HAHesham Al-Inany

Hesham Al-Inany

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hesham Al-Inany has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical outcome following stimulation with HMG versus highly purified HMG in patients undergoing ICSI

    by Ismail Aboul Foutouh, Sherif Khattab, Iman Abdel Mohesn, Mohamed Moaz, Hesham Al-Inany


  • Gonadotrophin-releasing hormone antagonists for assisted conception

    by Hesham G Al-Inany, Ahmed M Abou-Setta, Mohamed Aboulghar

    Gonadotrophin‐releasing hormone antagonists produce immediate suppression of gonadotrophin secretion, hence, they can be given after starting gonadotrophin administration. This has resulted in dramatic reduction in the duration of treatment cycle. Two different regimes have been described. The multiple‐dose protocol involves the administration of 0.25 mg cetrorelix (or ganirelix) daily from day six to seven of stimulation, or when the leading follicle is 14 to15 mm, until human chorionic gonadotrophin (HCG) administration and the single‐dose protocol involves the single administration of 3 mg cetrorelix on day seven to eight of stimulation. Assuming comparable clinical outcome, these benefits would justify a change from the standard long protocol of GnRH agonists to the new GnRH antagonist regimens. To evaluate the evidence regarding the efficacy of gonadotrophin‐releasing hormone (GnRH) antagonists with the standard long protocol of GnRH agonists for controlled ovarian hyperstimulation in assisted conception. We searched Cochrane Menstrual Disorders and Subfertility Group's Specialised Register, MEDLINE and EMBASE databases from 1987 to February 2006, and handsearched bibliographies of relevant publications and reviews, and abstracts of scientific meetings. We also contacted manufacturers in the field. Randomized controlled studies comparing different protocols of GnRH antagonists with GnRH agonists in assisted conception cycles were included in this review. Two authors independently assessed trial quality and extracted data. If relevant data were missing or unclear, the authors have been consulted Twenty seven RCTs comparing the GnRH antagonist to the long protocol of GnRH agonist fulfilled the inclusion criteria. Clinical pregnancy rate was significantly lower in the antagonist group. (OR = 0.84, 95% CI = 0.72 to 0.97). The ongoing pregnancy/ live‐birth rate showed the same significant lower pregnancy in the antagonist group (P = 0.03; OR 0.82, 95% CI 0.69 to 0.98). However, there was statistically significant reduction in incidence of severe OHSS with antagonist protocol. The relative risk ratio was (P = 0.01; RR 0.61, 95% CI 0.42 to 0.89). In addition, interventions to prevent OHSS (e.g. coasting, cycle cancellation) were administered more frequently in the agonist group (P = 0.03; OR 0.44, 95% CI 0.21 to 0.93). GnRH antagonist protocol is a short and simple protocol with good clinical outcome with significant reduction in incidence of severe ovarian hyperstimulation syndrome and amount of gonadotrophins but the lower pregnancy rate compared to the GnRH agonist long protocol necessitates counseling subfertile couples before recommending change from GnRH agonist to antagonist.


  • Metformin reduces abortion in pregnant women with polycystic ovary syndrome

    by Sherif Khattab, Iman Abdel Mohsen, Ismail Aboul Foutouh, Ashraf Ramadan, Mohamed Moaz, Hesham Al-Inany

    Background. Women with polycystic ovary syndrome (PCOS) are considered to be at increased risk of miscarriage. Since metformin has beneficial effects on the risk factors contributing to first-trimester abortion in PCOS patients, we hypothesized that metformin – owing to its metabolic, endocrine, vascular and anti-inflammatory effects – may reduce the incidence of first-trimester abortion in PCOS women. Materials and methods. A prospective cohort study was set up to determine the beneficial effects of metformin on PCOS patients during pregnancy. Two hundred non-diabetic PCOS patients were evaluated while undergoing assisted reproduction. One hundred and twenty patients became pregnant while taking metformin, and continued taking metformin at a dose of 1000–2000 mg daily throughout pregnancy. Eighty women who discontinued metformin use at the time of conception or during pregnancy comprised the control group. Results. Both groups were similar with respect to all background characteristics (age, body mass index, waist/hip ratio, follicle-stimulating hormone, luteinizing hormone, estradiol and dehydroepiandrosterone sulfate levels). Rates of early pregnancy loss in the metformin group were 11.6% compared with 36.3% in the control group (p < 0.0001; odds ratio = 0.23, 95% confidence interval 0.11–0.42). Conclusions. Administration of metformin throughout pregnancy to women with PCOS was associated with a marked and significant reduction in the rate of early pregnancy loss.


  • Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles

    by Mohamed Afm Youssef, Hesham G Al-Inany, Mohamed Aboulghar, Ragaa Mansour, Michelle Proctor


  • Ovulation induction in the new millennium: Recombinant follicle-stimulating hormone versus human menopausal gonadotropin

    by Hesham Al-Inany, Mohamed A Aboulghar, Ragaa T Mansour, Gamal I Serour

    The renewed interest in luteinizing hormone (LH), together with limited and decreasing health resources, make essential the comparison of high-cost, recombinant follicle-stimulating hormone (rFSH) preparations (devoid of LH) and human menopausal gonadotropin (hMG) in terms of clinical efficacy. All published, randomized controlled trials (RCTs) comparing rFSH versus hMG under different protocols of stimulation were examined. Eight true RCTs were included in this meta-analysis, recruiting 2031 participants. Data for ongoing pregnancy/live birth rate, clinical pregnancy rate, miscarriage rate, multiple pregnancy rate and ovarian hyperstimulation syndrome (OHSS) were extracted, and odds ratios (ORs) and 95% confidence intervals (CIs) were calculated with the use of a fixed-effects model. Data for the meta-analysis were combined using RevMan software (using the Mantel–Haenszel method). Pooling the results of these RCTs showed no significant difference between rFSH and hMG regarding the different outcomes: ongoing pregnancy/live birth rate, OR 1.18 (95% CI 0.93–1.50); clinical pregnancy rate, OR 1.2 (95% CI 0.99–1.47), miscarriage rate, OR 1.2 (95% CI 0.70–2.16); multiple pregnancy rate, OR 1.35 (95% CI 0.96–1.90); incidence of moderate/severe OHSS, OR 1.79 (95% CI 0.74–4.33). However, there was significant reduction in the amount of gonadotropins in favor of hMG over rFSH. There was no significant heterogeneity of treatment effect across the trials. In conclusion, there is no clinically significant difference between hMG and rFSH in in vitro fertilization/intracytoplasmic sperm injection cycles. Decision-makers should establish their choice of one drug over the other based on the most up-to-date evidence available.


  • Optimizing GnRH antagonist administration: meta-analysis of fixed versus flexible protocol

    by Hesham Al-Inany, Mohamed A Aboulghar, Ragaa T Mansour, Gamal I Serour


  • Peritoneal Closure vs. Non-Closure: Estimation of Pelvic Fluid by Transvaginal Ultrasonography after Abdominal Hysterectomy

    by Hesham Al-Inany

    Objective: To determine the volume of pelvic fluid and febrile morbidity after hysterectomy in which the peritoneum was or was not closed. Design: Prospective single-center study. Participants: Fifty-four women undergoing abdominal hysterectomy were enrolled in the study. Patients were randomized into two groups according to peritoneal closure: group I (n = 28) in which the peritoneum was closed, and group II (n = 26) in which the peritoneum was left open. All participants had early postoperative transvaginal ultrasound. Outcome Measures: Volume of pelvic fluid accumulated after hysterectomy, total leukocytic count before and after hysterectomy, body temperature over the first 24 h, and wound healing. Results: There was a statistically significant difference between both groups regarding the volume of pelvic fluid collection, the duration of the operation and number of ampoules needed (p < 0.05). There was no statistically significant difference regarding body temperature, TLC, and wound complications. Conclusion: Peritoneal non-closure does not increase short-term morbidity, however it does cause an increase in peritoneal pelvic fluid. The impact of this on long-term sequelae as adhesions should be investigated.